|
市場調査レポート
商品コード
1179470
エプスタインバーウイルス(EBV) - 市場考察、疫学、市場予測(2032年)Epstein Barr Virus (EBV) - Market Insight, Epidemiology and Market Forecast - 2032 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
エプスタインバーウイルス(EBV) - 市場考察、疫学、市場予測(2032年) |
出版日: 2022年12月01日
発行: DelveInsight
ページ情報: 英文 170 Pages
納期: 1~3営業日
|
当レポートでは、エプスタインバーウイルス(EBV)の主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。
DelveInsight's 'Epstein-Barr Virus - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Epstein-Barr Virus in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
The Epstein-Barr Virus market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted Epstein-Barr Virus market size from 2019 to 2032, segmented by the 7MM. The report also covers the current Epstein-Barr Virus treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Geographies Covered
Study period: 2019-2032
Epstein-Barr Virus Overview
Epstein-Barr Virus (EBV) is a common virus that remains dormant in most people. EBV causes infectious mononucleosis (IM) and has been associated with certain cancers, including Burkitt lymphoma, immunoblastic lymphoma, nasopharyngeal cancer, and stomach (gastric) cancer.
The transmission of EBV occurs in several ways, such as deep kissing or food-sharing. Increased levels of viral DNA are found in salivary secretions after the initial infection. Children can be infected after eating food that an EBV-infected individual has already chewed. The transmission has occurred through stem cells, organ transplantation, and blood transfusion.
The clinical presentation of the EBV infection usually overlaps with other acute viral syndromes caused by other viruses, such as Cytomegalovirus (CMV) and hepatitis viruses, which can lead to similar symptoms. Diagnostic schemes of EBV differ according to the patient's immune condition because the importance and urgency of therapeutic intervention differ between immunocompromised and immunocompetent individuals; a wide range of assays was utilized in diagnosing EBS.
Therapeutic strategies include prophylaxis, preemptive therapy, and targeted therapy. Rituximab, reduction of immunosuppression, and EBV-specific cytotoxic T-cell therapy are recommended as first-line therapy, whilst unselected donor lymphocyte infusions or chemotherapy are options as second-line therapy; other methods, including antiviral drugs, are discouraged.
Epstein-Barr Virus Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnoses available in the Epstein-Barr Virus market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Epstein-Barr Virus epidemiology division provides insights into the historical and current patient pool and the forecasted trend for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the prevalent patient pool, trends, and assumptions.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted Epstein-Barr Virus epidemiology segmented as the Diagnosed Incident Cases of Epstein-Barr Virus IM, Incident Cases of Epstein-Barr Virus + Cancer, Incident cases of Epstein-Barr Virus+ PTLD. The report includes the total Epstein-Barr Virus cases in the 7MM covering the United States, EU4 and the United Kingdom, and Japan from 2019 to 2032.
The epidemiology segment also provides the Epstein-Barr Virus epidemiology data and findings across the United States, EU4 and the United Kingdom, and Japan.
The total number of Epstein-Barr Virus IM cases in the 7MM countries was more than 1,120,000 in 2021.
As per the estimates, the United States had the highest number of incident cases of Epstein-Barr Virus in 2021. Among EU4 and the UK, Germany had the highest number of Epstein-Barr Virus cases, with more than 146,000 cases, followed by France in 2021. On the other hand, Spain had the lowest number of Epstein-Barr Virus cases, with close to 79,000 cases in 2021.
The drug chapter segment of the Epstein-Barr Virus report encloses a detailed analysis of Epstein-Barr Virus-marketed drugs and late-stage (Phase III, Phase II/III, and Phase II) pipeline drugs. It also helps understand the Epstein-Barr Virus clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Treatment generally supports mononucleosis; antipyretics and anti-inflammatory medications help treat fever, sore throat, and general fatigue in this illness. Hydration, rest, and good nutritional intake should also be encouraged. Corticosteroids are not generally recommended in the routine treatment of mononucleosis because of concerns with immunosuppression; however, in cases of airway obstruction, corticosteroids are indicated along with appropriate airway management.
Products detail in the report…
Epstein-Barr Virus Emerging Drugs
Drug developers are gradually shifting their attention toward Epstein-Barr Virus to meet the patient pool's current demands and counter the unmet needs of the therapeutic market.
Many molecules are in the pipeline to treat Epstein-Barr Virus-associated infection patients across many countries to cater to their needs. Some of the major late-stage products are likely to hit the market during our study period 2019-2032 include tabelecleucel (Atara Biotherapeutics), posoleucel (AlloVir), and Nanatinostat + valganciclovir (Viracta Therapeutics).
Tabelecleucel: Atara Biotherapeutics
Tabelecleucel (Atara Biotherapeutics) is an off-the-shelf, allogeneic T-cell immunotherapy based on Atara Biotherapeutics' allogeneic T-cell immunotherapy platform. The drug has received BTD in the US, EMA Priority Medicines (PRIME) in Europe, and ODD in the US and EU for treatment of EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT). The drug is currently in the late clinical phases for potentially treating patients with rituximab-refractory EBV+ PTLD. The therapy has received a marketing authorization recommendation from EMA in the EU for EBVALLO (tabelecleucel) to treat adult and pediatric patients who experience a serious complication following solid organ transplantation (SOT) or HCT called EBV+ PTLD.
Posoleucel (ALVR105): Allovir
Posoleucel (ALVR105), being investigated by AlloVir, is a multivirus specific T-cell therapy (VST) targeting five devastating viral pathogens: BK virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), EBV, and human herpesvirus 6 (HHV-6), that can transform care for transplant recipients as well as individuals who are at high risk for opportunistic viral infections by reducing or preventing disease morbidity and dramatically improving patient outcomes. The drug has received the ODD, PRIME designation in the EU, and RMAT designation from the US for treating serious infections with BKV, CMV, HHV-6, EBV, and/or AdV in allogeneic HSCT recipients. The therapy is currently being investigated in Phase II and III trials and is expected to get launched in the US market by 2024.
Products detail in the report…
The Epstein-Barr Virus market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Epstein-Barr Virus market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the Epstein-Barr Virus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
As per DelveInsight, the Epstein-Barr Virus market in the 7MM is expected to change in 2019-2032.
Key Findings
This section includes a glimpse of the Epstein-Barr Virus market in the 7MM. The Epstein-Barr Virus market size in the seven major markets was approximately USD 3,100 million in 2021.
This section provides the total Epstein-Barr Virus market size and the market size of Epstein-Barr Virus by therapies in the United States.
The United States accounts for the largest Epstein-Barr Virus market size than EU4 and the United Kingdom, and Japan.
This section provides the total Epstein-Barr Virus market size. It also provides Epstein-Barr Virus market size by therapies in Germany, France, Italy, Spain, and the United Kingdom.
This section provides the total Epstein-Barr Virus market size. It also provides the market size of Epstein-Barr Virus by therapies in Japan.
This section focuses on the uptake rate of potential drugs launched or expected to be launched in the market during 2019-2032. The analysis covers the Epstein-Barr Virus market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and making financial and regulatory decisions.
Epstein-Barr Virus Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II. It also analyses Epstein-Barr Virus's key players in developing targeted therapeutics.
Major players include Atara Biotherapeutics and Allovir, whose key products are expected to get launched in the US market by 2028.
Pipeline Development Activities
The report covers collaborations, acquisitions, mergers, licensing, and patent details for emerging Epstein-Barr Virus therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the Epstein-Barr Virus domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging treatment patterns or Epstein-Barr Virus market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform a competitive and market intelligence analysis of the Epstein-Barr Virus market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG matrix, market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Key Questions
Market Insights
Epidemiology Insights
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies